ResMed Inc. vs Solaredge Technologies Inc — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Solaredge Technologies Inc trades at $32.08 (market cap $2.00B). The key difference: ResMed Inc. is far larger — about 15.9× Solaredge Technologies Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Solaredge Technologies Inc for 34 Days on average.
| RMD | SEDG | |
|---|---|---|
Market Cap | $31.89B | $2.00B |
Volume | 618,314 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $277.88 | $78.51 |
52-Week Low | $182.82 | $28.47 |
Typical Hold Time | 51 Days | 34 Days |
Enterprise Value | $31.24B | $1.86B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
SolarEdge Technologies (SEDG) trades at $31.81, down 4.07% on the day, reflecting ongoing volatility amid a bearish technical signal and mixed earnings. The stock faces fundamental headwinds with a net loss of $405.45 million in 2025 and negative profit margins, though revenue grew to $1.18 billion. Recent news highlights legal investigations and AI data center initiatives, while analyst sentiment remains cautious with a $37.75 consensus target.
The outlook for SEDG is challenged by persistent losses and competitive pressures, but potential upside exists if AI-driven growth targets materialize. Key risks include execution on new initiatives, solar industry financing costs, and legal overhangs. Investors should weigh the high-risk profile against long-term transformation efforts under current market conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →